Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6000543

CCC(c1cccc(F)c1)c1ccccc1O.N

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.48
TYR P14679 1/20 0.48
ACHE P22303 1/20 0.48
TSHR P16473 2/20 0.47
HKDC1 Q2TB90 1/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
CNR2 P34972 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX15 P16050 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7164208 0.87 TSHR (0.57) BCHETYRACHETSHRHKDC1
Ammonia Solution, Strong SCHEMBL6001224 0.84 IDO1 (0.42) BCHETYRACHEHKDC1SLC6A2
Ammonia Solution, Strong SCHEMBL5999540 0.83 IDO1 (0.47) SLC6A2SLC6A4IDO1TDO2CNR2
Ammonia Solution, Strong SCHEMBL6001307 0.83 IDO1 (0.46) ACHESLC6A2SLC6A4IDO1TDO2
Ammonia Solution, Strong SCHEMBL6000870 0.83 IDO1 (0.41) ACHESLC6A2SLC6A4IDO1TDO2
SCHEMBL6000541 0.82 HRH1 (0.44) SLC6A2SLC6A4IDO1TDO2CNR2
SCHEMBL23126406 0.81 IDO1 (0.49) SLC6A2SLC6A4IDO1TDO2CNR2
SCHEMBL22048343 0.81 IDO1 (0.47) ACHESLC6A2SLC6A4IDO1TDO2
SCHEMBL1238318 0.81 TSHR (0.63) BCHETYRACHETSHRHKDC1
SCHEMBL23003618 0.80 TSHR (0.53) BCHETYRACHETSHRHKDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases MUELLER ALAN L 2006-06-29 US disclosed
US-6750244-B2 NERVOUS SYSTEM DISORDERS NPS PHARMACEUTICALS, INC. 2004-06-15 US disclosed
US-6211245-B1 DRUGS FOR CONTROLLING CALCIUM MODULATORS NPS PHARMACEUTICALS, INC. 2001-04-03 US disclosed
US-6017965-A TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA NPS PHARMACEUTICALS, INC. (US) 2000-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases NCS1, ATP2A1, CACNA1D BCHE 324/4885TYR 4621/4885ACHE 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.